IL287961A - Compositions and methods for treating lung conditions associated with biophiles - Google Patents

Compositions and methods for treating lung conditions associated with biophiles

Info

Publication number
IL287961A
IL287961A IL287961A IL28796121A IL287961A IL 287961 A IL287961 A IL 287961A IL 287961 A IL287961 A IL 287961A IL 28796121 A IL28796121 A IL 28796121A IL 287961 A IL287961 A IL 287961A
Authority
IL
Israel
Prior art keywords
compositions
methods
related lung
lung conditions
treating biofilm
Prior art date
Application number
IL287961A
Other languages
English (en)
Hebrew (he)
Inventor
Sean Farmer
Ken Alibek
Original Assignee
Locus Ip Co Llc
Sean Farmer
Ken Alibek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Locus Ip Co Llc, Sean Farmer, Ken Alibek filed Critical Locus Ip Co Llc
Publication of IL287961A publication Critical patent/IL287961A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL287961A 2019-05-10 2021-11-09 Compositions and methods for treating lung conditions associated with biophiles IL287961A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962846084P 2019-05-10 2019-05-10
PCT/US2020/032039 WO2020231786A1 (en) 2019-05-10 2020-05-08 Compositions and methods for treating biofilm-related lung conditions

Publications (1)

Publication Number Publication Date
IL287961A true IL287961A (en) 2022-01-01

Family

ID=73046991

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287961A IL287961A (en) 2019-05-10 2021-11-09 Compositions and methods for treating lung conditions associated with biophiles

Country Status (13)

Country Link
US (2) US11890341B2 (https=)
EP (1) EP3958869A4 (https=)
JP (1) JP2022531929A (https=)
KR (1) KR20210154872A (https=)
CN (1) CN114080236A (https=)
AU (1) AU2020276206A1 (https=)
BR (1) BR112021022632A2 (https=)
CA (1) CA3138922A1 (https=)
CR (1) CR20210618A (https=)
IL (1) IL287961A (https=)
MX (1) MX2021013663A (https=)
SG (1) SG11202112387UA (https=)
WO (1) WO2020231786A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5548121B2 (ja) 2007-05-14 2014-07-16 リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク バイオフィルム中の細菌細胞における生理学的分散応答の誘導
CN113873883A (zh) * 2019-03-15 2021-12-31 轨迹Ip有限责任公司 用于生物膜的强化治疗和预防的材料和方法
US20210069276A1 (en) * 2019-09-09 2021-03-11 LiquidPro Ltd. Ear spray device and ear protection composition for preventing water related ear canal disorders
US12334224B2 (en) * 2020-04-14 2025-06-17 Siemens Healthineers Ag Cardiovascular assessment of patients suspected of having COVID-19
US20230070870A1 (en) * 2021-09-09 2023-03-09 Robert V. West, III Covid Nasal Spray
BR102022016098A2 (pt) * 2022-08-12 2024-02-20 Universidade Estadual De Campinas Formulação antiviral e intranasal
CN115400105B (zh) * 2022-10-12 2023-08-22 湖北省农业科学院畜牧兽医研究所 焦棓酸在制备抗马链球菌兽疫亚种药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63182029A (ja) 1987-01-22 1988-07-27 Agency Of Ind Science & Technol リポソ−ム
EP0540074A1 (en) 1991-10-09 1993-05-05 ENIRICERCHE S.p.A. Cloning and sequencing of that chromosomal DNA region of bacillus subtilis comprising the SRFA operon which encodes the multienzymatic complex surfactin synthetase
JP2003246717A (ja) 2002-02-22 2003-09-02 Lion Corp 口腔用組成物
MXPA05013340A (es) 2003-06-09 2006-03-09 Nastech Pharm Co Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.
WO2009090656A2 (en) 2008-01-18 2009-07-23 Hadasit Medical Research Services & Development Ltd. Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
CA2760248C (en) 2009-04-30 2019-05-28 Actogenix Nv Cryoprotectants for freeze drying of lactic acid bacteria
EA037276B1 (ru) * 2010-04-27 2021-03-03 Лисандо Аг Способы устранения или уменьшения бактериальной биопленки
MX2014009103A (es) 2012-01-27 2015-11-18 Gfs Corp Aus Pty Ltd Métodos para producir biosurfactantes.
JP2014034552A (ja) * 2012-08-09 2014-02-24 Kao Corp バイオフィルム形成抑制剤
CN103007287A (zh) 2012-09-29 2013-04-03 湖州紫金生物科技有限公司 一种鼠李糖脂作为药物口服促吸收剂的应用
US9585903B2 (en) * 2013-09-30 2017-03-07 Council Of Scientific & Industrial Research Pharmaceutical composition comprising sophorolipid in combination with an antibiotic
US20170014437A1 (en) * 2014-04-03 2017-01-19 Syracuse University Synthetic disugar hydrocarbons as natural analogs to control microbial behaviors
CA2943049A1 (en) * 2014-04-08 2015-10-15 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
WO2015156904A1 (en) * 2014-04-08 2015-10-15 Aradigm Corporation Liposomes that form drug nanocrystals after freeze-thaw
US20170304411A1 (en) * 2014-10-24 2017-10-26 Hprd - Health Products Research And Development Lda Topical formulation for treating skin or mucosal infections, preparation method and uses thereof
WO2018049182A2 (en) * 2016-09-08 2018-03-15 Locus Solutions, Llc Distributed systems for the efficient production and use of microbe-based compositions

Also Published As

Publication number Publication date
MX2021013663A (es) 2022-01-24
US11890341B2 (en) 2024-02-06
CA3138922A1 (en) 2020-11-19
AU2020276206A1 (en) 2021-12-02
SG11202112387UA (en) 2021-12-30
US20200353085A1 (en) 2020-11-12
EP3958869A4 (en) 2022-11-16
CN114080236A (zh) 2022-02-22
BR112021022632A2 (pt) 2022-01-04
WO2020231786A1 (en) 2020-11-19
KR20210154872A (ko) 2021-12-21
CR20210618A (es) 2022-03-11
JP2022531929A (ja) 2022-07-12
EP3958869A1 (en) 2022-03-02
US20240181065A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
IL287961A (en) Compositions and methods for treating lung conditions associated with biophiles
SG11202104158SA (en) Composition and method for treating the lungs
ZA202006627B (en) Methods and compositions for treating cancer
IL286350A (en) Preparations and methods for the treatment of cancer
IL290833A (en) Preparations and methods for cll1 modification
IL288914A (en) Preparations and methods for the treatment of cancer
IL285886A (en) Preparations and methods for the treatment of laminopathy
ZA202104870B (en) Methods and compositions for treating cancer
IL285796A (en) Methods and preparations for the treatment of cancer
IL278814A (en) Methods and preparations for the treatment of pulmonary hypertension
SG11202012435UA (en) Compositions and methods for treating cancer
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
IL287982A (en) Preparations and methods for the treatment of cancer
IL277779A (en) Preparations and methods for the treatment of macular degeneration
IL282100A (en) Methods and compounds for treating oral mucositis
EP3883588A4 (en) COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS
IL286153A (en) Methods and preparations for the treatment of cancer
IL277463A (en) Vehicles and methods for treating itch
ZA202007183B (en) Compositions and methods for treating the eye
SG11202010911WA (en) Methods and compositions for treating chronic urticaria
IL288440A (en) Materials and methods for the treatment of retinopathy
SG11202107355RA (en) Improved method and compositions for surface treatment
IL288478B2 (en) Methods, compositions and devices for treating neuroinflammatory conditions
SG11202104692VA (en) Compositions and methods for treating cancer
GB2579687B (en) Composition and method